Stocks Down Under Videos
Get a 3-month FREE TRIAL to CONCIERGE now!
Concierge gives you timely BUY and SELL alerts on ASX-listed stocks
Percheron Therapeutics (ASX:PER): Interview with CEO Dr James Garner
July 7, 2025
PER, Percheron Therapeutics
Percheron Therapeutics (ASX:PER)
We spoke to Dr James Garner, CEO of Percheron Therapeutics (ASX:PER), about the company’s new lead candidate, a cancer immunotherapy drug called HMBD-002, which it just in-licensed from Singapore’s Hummingbird Bioscience.
This drug has completed a 48-patient Phase 1 across multiple tumour types. The drug has an excellent safety profile, with no dose limiting toxicities reached and only a modest level of treatment-related adverse events, and several patients showed encouraging duration of response.
Percheron Therapeutics is excited about the potential for this drug given what is known about its target, the immune checkpoint VISTA. At the moment you can buy Percheron Therapeutics for about cash backing.
Looking for the Best ASX Life Sciences stocks to invest in right now?
